The amount of a protein called ATG5 in tears may pinpoint people whose dry eye symptoms are related to Sjögren’s syndrome with greater accuracy than standard diagnostic tests, a study has found. However, ATG5’s potential as a biomarker of the disorder should be investigated further, the researchers said. The…
News
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review to an application for Esbriet (pirfenidone) as a treatment for unclassifiable interstitial lung disease (UILD). The supplemental new drug application was submitted by Genentech, Esbriet’s developer and a member of the Roche Group, based on…
Tocilizumab, a medicine approved for certain types of arthritis, may be a safe and effective approach for treating severe respiratory distress associated with COVID-19 in people with autoimmune conditions, the case of an elderly Sjögren’s syndrome patient suggests. The report, “…
Use of oral pilocarpine increased salivary flow in people with dry mouth due to primary Sjögren’s syndrome or other health conditions in a small study. However, the medication did not significantly alter dental health or the structure of the salivary glands, as assessed via ultrasound. The study, “…
An international trial is recruiting people with Sjögren’s syndrome to investigate the feasibility of an online app, called Sjogo, that’s designed to support the self-management of symptoms. Recruitment is primarily being done via Twitter, the American microblogging and social networking service. The Sjogo app…
The Sjögren’s Foundation is recommending that people with Sjögren’s syndrome ages 16 and older be vaccinated against COVID-19 infection, and advices patients to talk with their healthcare provider about potential decisions and vaccination timing. The recommendation, released online in a statement, was based on safety and effectiveness…
In-hospital mortality, the length of a hospital stay, and hospitalization charges for people with acute kidney injury and Sjögren’s syndrome are no different from those without Sjögren’s, a large-scale database analysis found. An interesting finding of the analysis was…
A technique that delivers low electric currents to stimulate specific parts of the brain can safely reduce fatigue in people with primary Sjogren’s syndrome (pSS), a pilot study has found. Transcranial direct-current stimulation (tDCS) also helped patients in the areas of…
People with Sjögren’s syndrome and other systemic autoimmune rheumatic diseases (SARDs) may be at a greater risk of severe complications from COVID-19 than people without these disorders, a study reports. Specifically, SARDs patients are more likely to develop venous thromboembolism (VTE), or blood clots in…
RSLV-132, an investigational treatment for autoimmune conditions, led to significant and clinically meaningful reductions in patient-reported fatigue in people with primary Sjögren’s syndrome, results from a Phase 2 clinical trial show.
Recent Posts
- Efgartigimod shows signals of benefit in Sjögren’s disease clinical trial
- Sjögren’s symptoms differ by sex, but overall impact similar
- Sjögren’s symptoms extend far beyond dryness, U.S. survey finds
- Study links anti-Ro antibody patterns to disease features in Sjögren’s
- Global trial of telitacicept for Sjögren’s doses first patient ‘within weeks’
- Patients, advocates working this month to raise awareness of Sjögren’s
- Biotech, US university partner on new ways to speed Sjögren’s diagnosis
- New study links alternative splicing patterns to Sjögren’s severity
- Initial data from trial testing CLN-978 in Sjögren’s expected this year
- Sjögren’s disease may increase risk of certain digestive cancers: Korean study